Merck & Co., Inc. (ETR:6MK)
93.90
-1.40 (-1.47%)
At close: Jan 12, 2026
Merck & Co. Revenue
Merck & Co. had revenue of $17.28B USD in the quarter ending September 30, 2025, with 3.72% growth. This brings the company's revenue in the last twelve months to $64.24B, up 1.68% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$64.24B
Revenue Growth
+1.68%
P/S Ratio
4.31
Revenue / Employee
$856.47K
Employees
75,000
Market Cap
235.85B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Merck & Co. News
- 8 hours ago - Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? - Nasdaq
- 15 hours ago - 3 Dividend Stocks to Hold for the Next 10 Years - The Motley Fool
- 1 day ago - Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
- 1 day ago - The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips - Forbes
- 2 days ago - Key deals this week: Merck, Glencore, CrowdStrike, Marvell Technology, Steel Dynamics and more - Seeking Alpha
- 2 days ago - Notable analyst calls this week: Palantir, Merck and Lockheed Martin among top picks - Seeking Alpha
- 2 days ago - January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy - Seeking Alpha
- 3 days ago - Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD) for $30 Billion - GuruFocus